The Journal of Sexual Medicine, Journal Year: 2024, Volume and Issue: 22(2), P. 215 - 216
Published: Dec. 1, 2024
Language: Английский
Diabetes & Metabolism, Journal Year: 2025, Volume and Issue: unknown, P. 101612 - 101612
Published: Jan. 1, 2025
Language: Английский
Citations
3
Pharmacological Research, Journal Year: 2024, Volume and Issue: 207, P. 107312 - 107312
Published: July 18, 2024
Addiction is a chronic relapsing disease with high morbidity and mortality. Treatments for addiction include pharmacological psychosocial interventions; however, currently available medications are limited in number efficacy. The glucagon-like-peptide-1 (GLP-1) system emerging as potential novel pharmacotherapeutic target alcohol other substance use disorders (ASUDs). In this review, we summarize discuss the wealth of evidence from testing GLP-1 receptor (GLP-1R) agonist preclinical models humans ASUDs, possible mechanisms underlying impact GLP-1R agonists on alcohol/substance use, gaps knowledge, future directions. Most research has been conducted relation to use; psychostimulants, opioids, nicotine have also investigated. Preclinical suggests that reduce related outcomes. main proposed reward processing, stress, cognitive function, well broader satiety, changes gastric motility, glucose homeostasis. More in-depth mechanistic studies warranted. Clinical their findings less conclusive; most support safety efficacy ASUD treatment. Identifying preferred compounds, subgroups who responsive some key questions translate promising data into clinical settings. Several trials underway test people ASUDs.
Language: Английский
Citations
13
Cancers, Journal Year: 2024, Volume and Issue: 17(1), P. 78 - 78
Published: Dec. 30, 2024
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated significant efficacy in obesity treatment beyond their original development for type-2 diabetes management. This comprehensive study investigated the relationship between GLP-1RA use and cancer incidence individuals with across a 5-year follow-up period. Methods: We conducted large-scale cohort using TriNetX US Collaborative Network database (2013–2023) examining adult patients obesity. The utilized propensity score matching to pair GLP-1RA-treated controls (1:1) nearest neighbor method. Cancer served as primary outcome measure over follow-up, subgroup analyses considering individual agents, patient sex, BMI categories. Results: Analysis revealed cancer-risk reductions associated multiple types compared matched controls. Notable risk were observed gastrointestinal (HR 0.67, 95% CI 0.59–0.75), skin 0.62, 0.55–0.70), breast 0.72, 0.64–0.82), female genital 0.61, 0.53–0.71), prostate 0.68, 0.58–0.80), lymphoid/hematopoietic cancers 0.69, 0.60–0.80). Semaglutide superior protective effects, particularly 0.45, 0.37–0.53). Conversely, liraglutide showed increased risks thyroid 1.70, 1.03–2.82) respiratory 1.62, 1.13–2.32). Conclusions: research provides compelling evidence GLP-1RA’s potential role reduction, semaglutide showing promising results. differential effects among agents emphasize importance of personalized medicine approaches. These findings suggest implications clinical practice future both management prevention.
Language: Английский
Citations
8
Emerging Trends in Drugs Addictions and Health, Journal Year: 2024, Volume and Issue: 4, P. 100157 - 100157
Published: Sept. 3, 2024
Semaglutide, a Glucagon-like peptide 1 (GLP-1) receptor agonist marketed under the brand name Ozempic, is originally prescribed for diabetes treatment and obesity management. However, healthy individuals without medical cause use Ozempic supervision to improve their physical appearance - trend that has proliferated through social media, news coverage, relevant celebrity endorsements. Thus, exploring media posts can provide insight into understanding individuals' experiences, beliefs, motivation, as well misconceptions about Ozempic. To do so, this study utilizes BERTopic, natural language processing approach topic modeling, analyze 46,491 Reddit from three subreddits (r/ozempic, r/ozempicforweightloss, r/semaglutide) dated between April 2019 December 2023. The analysis revealed various discussion topics, including using weight loss, dosaging, insurance denial due lack of diagnosis, loss tracking, side effect Overall, overarching theme centered on off-label its GLP-1 counterparts purposes. Moreover, awareness health hazards associated with unsupervised an image enhancer not frequently appear in discussions. These findings, supported by dynamic modeling analysis, offer ecological insights experiences opinions community members Ozempic-related subreddits, reinforcing growing evidence drug's increasing popularity management role played media. also shows how information campaigns risks may help counterbalance risk detected
Language: Английский
Citations
7
Diabetes/Metabolism Research and Reviews, Journal Year: 2025, Volume and Issue: 41(2)
Published: Feb. 1, 2025
ABSTRACT Background and Objective Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are widely used to treat type 2 diabetes obesity, providing metabolic cardiovascular benefits. However, concerns have emerged about potential neuropsychiatric side effects, including suicidal ideation behaviour, prompting investigations by regulatory bodies such as the FDA EMA. This systematic review meta‐analysis aimed assess association between GLP‐1RA use risk of or behaviour. Methods A literature search was conducted in PubMed, Embase, Web Science through September 2024, adhering PRISMA guidelines. Observational cohort case‐control studies reporting behaviour adults using GLP‐1RAs were included. The Modified Newcastle‐Ottawa Scale assessed bias, random‐effect models calculated ratios (RR) with 95% confidence intervals (CIs). Heterogeneity I statistic. Results Of 126 studies, 11 included from multiple countries diverse designs. four showed no statistically significant difference outcomes users other anti‐hyperglycaemic drugs (RR: 0.568, CI: 0.077–4.205). Substantial heterogeneity observed (I = 98%). Pharmacovigilance indicated disproportionate increase suicidality, while some observational suggested a lower risk. Conclusion found link increased high reliance on pharmacovigilance data suggest caution. Clinicians should monitor patients, particularly those psychiatric conditions, further research is needed long‐term safety.
Language: Английский
Citations
1
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(18), P. 10173 - 10173
Published: Sept. 22, 2024
The insulin–heart axis plays a pivotal role in the pathophysiology of cardiovascular disease (CVD) insulin-resistant states, including type 2 diabetes mellitus. Insulin resistance disrupts glucose and lipid metabolism, leading to systemic inflammation, oxidative stress, atherogenesis, which contribute heart failure (HF) other CVDs. This review was conducted by systematically searching PubMed, Scopus, Web Science databases for peer-reviewed studies published past decade, focusing on therapeutic interventions targeting axis. Studies were selected based their relevance insulin resistance, outcomes, efficacy pharmacologic treatments. Key findings from highlight lifestyle modifications, such as dietary changes physical activity, remain cornerstone managing improving outcomes. Moreover, interventions, metformin, sodium–glucose cotransporter inhibitors, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 have shown reducing risk addressing metabolic dysfunction, endothelial function. Furthermore, emerging treatments, angiotensin receptor–neprilysin mechanical like ventricular assist devices offer new avenues HF patients. potential these therapies improve left ejection fraction reverse pathological cardiac remodeling highlights importance early intervention. However, challenges optimizing treatment regimens understanding long-term effects agents. Future research should focus personalized approaches that integrate effectively target mitigate burden complications populations.
Language: Английский
Citations
6
Progress in Cardiovascular Diseases, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 1, 2024
Language: Английский
Citations
4
Pharmacological Research, Journal Year: 2025, Volume and Issue: unknown, P. 107734 - 107734
Published: April 1, 2025
Drug discovery before the 20th century often focused on single genes, molecules, cells, or organs, failing to capture complexity of biological systems. The emergence protein-protein interaction network studies in 2001 marked a turning point and promoted holistic approach that considers human body as an interconnected system. This is particularly evident study bidirectional interactions between central nervous system (CNS) peripheral which are critical for understanding health disease. Understanding these complex requires integrating multi-scale, heterogeneous data from molecular organ levels, encompassing both omics (e.g., genomics, proteomics, microbiomics) non-omics imaging, clinical phenotypes). Artificial intelligence (AI), multi-modal models, has demonstrated significant potential analyzing CNS-peripheral by processing vast, datasets. Specifically, AI facilitates identification biomarkers, prediction therapeutic targets, simulation drug effects multi-organ systems, thereby paving way novel strategies. review highlights AI's transformative role research, focusing its applications unraveling disease mechanisms, discovering optimizing trials through patient stratification adaptive trial design.
Language: Английский
Citations
0
Health Expectations, Journal Year: 2025, Volume and Issue: 28(2)
Published: April 1, 2025
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are a pharmacological treatment option for both diabetes and weight loss. Qualitative evidence is vital in providing greater understanding of patients, practitioners carers experience taking or delivering GLP‐1 RAs. This can inform the current future configuration delivery services. We conducted scoping review to better understand quantity, nature key characteristics qualitative primary which explores experiences, views perceptions clinicians regarding use Methods Four bibliographic databases were searched on 10 July 2024: MEDLINE, APA PsycInfo via Ovid, CINAHL Ultimate EBSCOhost, ProQuest Dissertations Theses Global ProQuest. also Google Scholar, two clinical trials registries, pre‐print server medRxiv citation searches. sought research about experiences any aspect prescribing GLP‐1RAs, indication. Study selection data extraction performed by independent reviewers. The included studies collated, their described. Results After de‐duplication 1545 titles abstracts screened relevance, with 77 full‐text articles assessed eligibility, resulting 25 studies. More focused type 2 ( n = 12) than loss 9) indication 4). not represented. No one area (e.g. different indications viewpoints) was well represented, either due absence narrow focus lack an in‐depth analytical approach. Conclusion Whilst exploring patient clinician RAs identified this review, findings highlight need more robust be across all user groups, particular involving carers, especially within service settings. gap needs urgently addressed ensure appropriately prescribed patients receive support from services suited needs. Patient Public Contribution Seventeen public collaborators contributed search suggesting additional terms, helping define population inclusion contributing protocol development. Their thoughts helped form basis discussion paper.
Language: Английский
Citations
0
International Journal of Impotence Research, Journal Year: 2025, Volume and Issue: unknown
Published: April 16, 2025
Language: Английский
Citations
0